Related Experiment Video

Updated: Sep 8, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside

Chiara Palandri1, Lorenzo Santini1, Alessia Argirò2

  • 1Department NeuroFarBa, University of Florence, Florence, Italy.

Drugs
|June 13, 2022
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) lacks specific drug treatments, hindering clinical trials. Recent novel therapies targeting myosin show promise for this inherited heart disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Genetics

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease.
  • Current treatments for HCM rely on non-selective drugs and expert consensus due to limited large-scale trials.
  • Existing therapies are often insufficient or poorly tolerated by patients.

Purpose of the Study:

  • To critically review established and novel drug therapies for hypertrophic cardiomyopathy.
  • To evaluate the efficacy and tolerability of different drug classes in HCM patients.
  • To discuss the potential of new selective agents targeting HCM pathophysiology.

Main Methods:

  • Review of existing literature on drug treatments for HCM.
  • Analysis of clinical trial data for both old and new therapeutic agents.
  • Discussion of preclinical findings and their translation to patient care.

Main Results:

  • Established therapies for HCM, including disopyramide and beta-blockers, primarily manage symptoms of outflow tract obstruction.
  • Previous attempts with novel drugs targeting HCM-specific pathways have shown limited efficacy or poor patient tolerance.
  • Emerging therapies focus on allosteric myosin inhibition to directly address hypercontractility and altered energetics in HCM.

Conclusions:

  • There is an unmet need for effective, specific drug treatments for hypertrophic cardiomyopathy.
  • Novel myosin-targeting agents represent a promising new direction for HCM pharmacotherapy.
  • Further research and clinical trials are essential to establish the role of new drugs in managing HCM.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K
Preparation of Human Myocardial Tissue for Long-Term Cultivation10:58

Preparation of Human Myocardial Tissue for Long-Term Cultivation

Published on: June 2, 2022

4.9K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
30
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505